[Effect of erythropoietin on tissue factor and tissue factor pathway inhibitor in uremic hemodialysis patients].
Some parameters of extrinsic coagulation pathway, including concentration and activity of tissue factor and concentration of tissue factor pathway inhibitor, have been estimated in uremic hemodialysis patients. The impact of erythropoietin treatment on the extrinsic coagulation pathway has also been the aim of the study. Increased concentration of tissue factor pathway inhibitor--TFPI has been found both in dialysed and non-dialysed uremic patients. This finding may be the evidence of endothelial damage as well as the protective factor against thrombotic complications. Erythropoietin treatment seemed not to induce statistically significant changes in extrinsic coagulation pathway. Some results indicate that estimation of "truncated' and "full length" forms of TFPI may be more useful comparing to complete TFPI concentration.
Bronowicz
Anna
A
Oddział Nefrologii ze Stacja Dializ i Pododdziałem Onkologii Szpitala Wojewódzkiego w Lomzy.
Perkowski
Henryk
H
Pawlak
Krystyna
K
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D013925:Thromboplastin / Q000187:drug effects*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014511:Uremia / Q000378:metabolism* / Q000628:therapy
D000925:Anticoagulants; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D004921:Erythropoietin; D013925:Thromboplastin